• Human Endogenous Retroviruses linked to MS, Type 1 diabetes, ALS, schizophrenia
  • GeNeuro’s temelimab most advanced drug candidate targeting pathogenic HERV

Geneva, Switzerland,  11 July 2019 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), announced today publication of a review in Frontiers in Genetics, which has compiled growing evidence of the link between human endogenous retroviruses (HERVs) and many difficult to treat neurological disorders.

For more information, please access following link :